Apitegromab (anti-GDF8), 生长/分化因子 8 抑制剂

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
功能和特点
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human)
  • 亚型: Human IgG4SP
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab175456-100μg
100μg 现货 Stock Image
Ab175456-1mg
1mg 现货 Stock Image
Ab175456-5mg
5mg 现货 Stock Image
Ab175456-10mg
10mg 期货 Stock Image

基本信息

产品名称 Apitegromab (anti-GDF8), 生长/分化因子 8 抑制剂
别名 阿匹特古单抗 | Apitegromab(抗 GDF8)
英文别名 GDF 8 antibody | GDF-8 antibody | GDF8 antibody | GDF8_HUMAN antibody | Growth differentiation factor 8 antibody | Growth/differentiation factor 8 antibody | MSLHP antibody | MSTN antibody | Myostatin antibody | OTTHUMP00000163498 antibody | GDF8 | GDF-8
规格或纯度 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 MSTN
种属反应性 人(Human)
偶联 Unconjugated
作用类型 抑制剂
作用机制 生长/分化因子 8 抑制剂

产品属性

克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 lambda
SDS-PAGE 27.9 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 187.0 kDa, under non-reducing conditions.
纯化方法 Protein A purified
纯度 >95%
物理外观 Liquid
储存缓冲液 Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息 2278276-46-1
分子类型 抗体

图片

Apitegromab (anti-GDF8) (Ab175456) - SEC
The purity of Apitegromab (anti-GDF8) (Ab175456) is more than 95% verified by HPLC.

关联靶点(人)

MSTN Tclin 生长/分化因子 8(Growth/differentiation factor 8) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

安全和危险性(GHS)

质量标准

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到3个结果

批号(Lot Number) 证书类型 日期 货号
ZJ24F0405066 分析证书 24-04-30 Ab175456
ZJ24F0405065 分析证书 24-04-30 Ab175456
ZJ24F0405064 分析证书 24-04-30 Ab175456

可替换产品

参考文献

1. Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E et al..  (2019)  Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy..  Hum Mol Genet,  28  (7): (1076-1089).  [PMID:30481286]
2. Takayama K, Noguchi Y, Aoki S, Takayama S, Yoshida M, Asari T, Yakushiji F, Nishimatsu S, Ohsawa Y, Itoh F, Negishi Y, Sunada Y, Hayashi Y..  (2015)  Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition..  J Med Chem,  58  (3): (1544-1549).  [PMID:25569186] [10.1021/jm501170d]
3. Zhu J, Mishra RK, Schiltz GE, Makanji Y, Scheidt KA, Mazar AP, Woodruff TK..  (2015)  Virtual High-Throughput Screening To Identify Novel Activin Antagonists..  J Med Chem,  58  (14): (5637-5648).  [PMID:26098096] [10.1021/acs.jmedchem.5b00753]
4. Asari T, Takayama K, Nakamura A, Shimada T, Taguchi A, Hayashi Y..  (2017)  Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide..  ACS Med Chem Lett,  (1): (113-117).  [PMID:28105285] [10.1021/acsmedchemlett.6b00420]
5. Rentier C, Takayama K, Saitoh M, Nakamura A, Ikeyama H, Taguchi A, Taniguchi A, Hayashi Y..  (2019)  Design and synthesis of potent myostatin inhibitory cyclic peptides..  Bioorg Med Chem,  27  (7): (1437-1443).  [PMID:30777663] [10.1016/j.bmc.2019.02.019]
6. McPherron, A C AC and Lee, S J SJ..  (1997)  Double muscling in cattle due to mutations in the myostatin gene..  Proceedings of the National Academy of Sciences of the United States of America,  (11): [PMID:9356471]
7. Gonzalez-Cadavid, N F NF and 12 more authors..  (1998)  Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting..  Proceedings of the National Academy of Sciences of the United States of America,  (8): [PMID:9843994]
8. Hill, Jennifer J JJ, Qiu, Yongchang Y, Hewick, Rodney M RM and Wolfman, Neil M NM..  (2003)  Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains..  Molecular endocrinology (Baltimore, Md.),  [PMID:12595574]
9. Schuelke, Markus M and 8 more authors..  (2004)  Myostatin mutation associated with gross muscle hypertrophy in a child..  The New England journal of medicine,  (24): [PMID:15215484]
10. Saunders, Matthew A MA and 5 more authors..  (2006)  Human adaptive evolution at Myostatin (GDF8), a regulator of muscle growth..  American journal of human genetics,  [PMID:17186467]
11. Takehara-Kasamatsu, Yuka Y and 11 more authors..  (2007)  Characterization of follistatin-related gene as a negative regulatory factor for activin family members during mouse heart development..  The journal of medical investigation : JMI,  [PMID:17878677]
12. Apgar, James R JR and 13 more authors..  (2016)  Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody..  mAbs,  [PMID:27625211]
13. Walker, Ryan G RG and 16 more authors..  (2017)  Structural basis for potency differences between GDF8 and GDF11..  BMC biology,  (3): [PMID:28257634]

溶液计算器